SF3B1 mutations in chronic lymphocytic leukemia

被引:99
作者
Wan, Youzhong [1 ,2 ]
Wu, Catherine J. [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
SPLICING FACTOR; MYELODYSPLASTIC SYNDROMES; CLINICAL-SIGNIFICANCE; RING SIDEROBLASTS; CLONAL EVOLUTION; MACHINERY; PATHWAY; ABERRATIONS; PROGRESSION; NOTCH1;
D O I
10.1182/blood-2013-02-427641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre-mRNA splicing has been detected in CLL cases with SF3B1 mutations. Although the causative link between SF3B1 mutation and CLL pathogenesis remains unclear, several lines of evidence suggest SF3B1 mutation might be linked to genomic stability and epigenetic modification.
引用
收藏
页码:4627 / 4634
页数:8
相关论文
共 50 条
  • [31] SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
    Lin, Chien-Chin
    Hou, Hsin-An
    Chou, Wen-Chien
    Kuo, Yuan-Yeh
    Wu, Shang-Ju
    Liu, Chieh-Yu
    Chen, Chien-Yuan
    Tseng, Mei-Hsuan
    Huang, Chi-Fei
    Lee, Fen-Yu
    Liu, Ming-Chih
    Liu, Chia-Wen
    Tang, Jih-Luh
    Yao, Ming
    Huang, Shang-Yi
    Hsu, Szu-Chun
    Ko, Bor-Sheng
    Tsay, Woei
    Chen, Yao-Chang
    Tien, Hwei-Fang
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) : E109 - E115
  • [32] Mutant SF3B1 promotes malignancy in PDAC
    Simmler, Patrik
    Ioannidi, Eleonora I.
    Mengis, Tamara
    Marquart, Kim Fabiano
    Asawa, Simran
    Van-Lehmann, Kjong
    Kahles, Andre
    Thomas, Tinu
    Schwerdel, Cornelia
    Aceto, Nicola
    Ratsch, Gunnar
    Stoffel, Markus
    Schwank, Gerald
    ELIFE, 2023, 12
  • [33] Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations
    Song, Jinming
    Moscinski, Lynn
    Yang, Ethan
    Shao, Haipeng
    Hussaini, Mohammad
    Zhang, Hailing
    IN VIVO, 2023, 37 (03): : 985 - 993
  • [34] Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts
    Seo, Ja Young
    Lee, Ki-O
    Kim, Sun-Hee
    Kim, Kihyun
    Jung, Chul Won
    Jang, Jun Ho
    Kim, Hee-Jin
    ANNALS OF HEMATOLOGY, 2014, 93 (04) : 603 - 608
  • [35] Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
    Zuo, Zhuang
    Medeiros, L. Jeffrey
    Garces, Sofia
    Routbort, Mark J.
    Ok, Chi Young
    Loghavi, Sanam
    Kanagal-Shamanna, Rashmi
    Jelloul, Fatima Zahra
    Garcia-Manero, Guillermo
    Chien, Kelly L. S.
    Patel, Keyur S. P.
    Luthra, Rajyalakshmi
    Yin, C. Cameron
    BIOLOGY-BASEL, 2023, 12 (01):
  • [36] Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
    Patnaik, Mrinal M.
    Lasho, Terra L.
    Finke, Christy M.
    Hanson, Curtis A.
    Hodnefield, Janice M.
    Knudson, Ryan A.
    Ketterling, Rhett P.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (03) : 201 - 206
  • [37] Uveal Melanomas with SF3B1 Mutations A Distinct Subclass Associated with Late-Onset Metastases
    Yavuzyigitoglu, Serdar
    Koopmans, Anna E.
    Verdijk, Robert M.
    Vaarwater, Jolanda
    Eussen, Bert
    van Bodegom, Alice
    Paridaens, Dion
    Kilic, Emine
    de Klein, Annelies
    OPHTHALMOLOGY, 2016, 123 (05) : 1118 - 1128
  • [38] Impact of SF3B1 mutation in myelofibrosis
    Senapati, Jayastu
    Verstovsek, Srdan
    Masarova, Lucia
    Pemmaraju, Naveen
    Patel, Keyur P.
    Montalban-Bravo, Guillermo
    Pierce, Sherry A.
    Zhou, Lingsha
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Bose, Prithviraj
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2701 - 2705
  • [39] Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
    Malcovati, Luca
    Papaemmanuil, Elli
    Bowen, David T.
    Boultwood, Jacqueline
    Della Porta, Matteo G.
    Pascutto, Cristiana
    Travaglino, Erica
    Groves, Michael J.
    Godfrey, Anna L.
    Ambaglio, Ilaria
    Galli, Anna
    Da Via, Matteo C.
    Conte, Simona
    Tauro, Sudhir
    Keenan, Norene
    Hyslop, Ann
    Hinton, Jonathan
    Mudie, Laura J.
    Wainscoat, James S.
    Futreal, P. Andrew
    Stratton, Michael R.
    Campbell, Peter J.
    Hellstrom-Lindberg, Eva
    Cazzola, Mario
    BLOOD, 2011, 118 (24) : 6239 - 6246
  • [40] Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
    Dalton, W. Brian
    Helmenstine, Eric
    Walsh, Noel
    Gondek, Lukasz P.
    Kelkar, Dhanashree S.
    Read, Abigail
    Natrajan, Rachael
    Christenson, Eric S.
    Roman, Barbara
    Das, Samarjit
    Zhao, Liang
    Leone, Robert D.
    Shinn, Daniel
    Groginski, Taylor
    Madugundu, Anil K.
    Patil, Arun
    Zabransky, Daniel J.
    Medford, Arielle
    Lee, Justin
    Cole, Alex J.
    Rosen, Marc
    Thakar, Maya
    Ambinder, Alexander
    Donaldson, Joshua
    DeZern, Amy E.
    Cravero, Karen
    Chu, David
    Madero-Marroquin, Rafael
    Pandey, Akhilesh
    Hurley, Paula J.
    Lauring, Josh
    Park, Ben Ho
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (11) : 4708 - 4723